Pharmamarketeer

AstraZeneca’s phase III trial of AZD1222 demonstrates significant vaccine efficacy of 79% at preventing symptomatic Covid─19

The AstraZeneca US phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic Covid─19 and 100% efficacy at preventing severe disease and hospitalisation.

Advertentie(s)